Reference Sourcing and Traceability for Bioequivalence

Data Characteristics in this Category

Bioequivalence study data primarily originate from clinical trial reports, analytical method validation reports, statistical analysis reports, and relevant regulatory guidelines. This data exists in both structured formats (e.g., clinical trial databases, analysis result tables) and unstructured formats (e.g., study protocols, ethical approvals, subject informed consent forms, raw data records, investigator brochures, adverse event reports, document audit trails, meeting minutes). Regarding update frequency, core clinical data stabilize after trial completion. However, updates to regulatory requirements, guidelines, and post-market surveillance data may necessitate supplementary studies or report revisions, leading to new document versions. Document structure typically follows ICH E3 or NMPA (National Medical Products Administration) guidelines, with reports including standard sections like abstract, introduction, methodology, results, discussion, and conclusion. Fields and units involve pharmacokinetic parameters (e.g., AUC, Cmax, Tmax), biostatistical indicators (e.g., confidence intervals), and dosage, concentration, and time. Units strictly adhere to international standards (e.g., ng/mL, h, mg).

Constraints Imposed by These Characteristics on "Reference Sourcing and Traceability"

The diversity and complexity of bioequivalence data demand high precision in reference sourcing. Key information in unstructured documents may be scattered across different sections, requiring efficient extraction and correlation. The dynamic nature of regulatory guidelines necessitates version control capabilities in the knowledge base to ensure compliance and timeliness of references. The specialized nature of pharmacokinetic parameters and statistical indicators requires recall results to accurately identify and present these critical data points, avoiding ambiguity. Cross-referencing between documents is frequent; for example, a clinical report may cite an analytical method validation report. This demands a traceability mechanism capable of traversing multiple document layers. Furthermore, the rigor of bioequivalence studies dictates that any citation must explicitly point to the original source, facilitating auditing and verification, and preventing information silos or misunderstandings.

Configuration Settings

Configuration Item	Recommended Value	Rationale
`Chunk size` (Chunk Size)	`800–1200 characters`	Ensures a single chunk contains complete pharmacokinetic or statistical discussions, preventing semantic breaks.
`Recall count` (Recall Count)	`Top 8–12 entries`	Covers key information from multiple related documents, such as clinical reports, analysis reports, and regulatory requirements.
`Similarity threshold` (Similarity Threshold)	Calibrate based on actual measurements, suggested `0.75–0.85` range	Balances recall comprehensiveness and precision, avoiding interference from irrelevant or low-relevance content.
`Rerank result count` (Rerank Return Count)	`Top 5 entries`	Prioritizes presenting core evidence most directly relevant to the user's query, improving response efficiency.
`PARSE_FILE_TIMEOUT_SECONDS`	`600 seconds`	Addresses the complex parsing requirements of large clinical trial reports or PDF documents.
`maxContext`	`4000–8000 Tokens`	Ensures the model has sufficient context to understand and integrate the complex logic of bioequivalence studies.

Three Common Mistakes

Symptom: The model's output reference source is empty or points to irrelevant documents. Reason: The Similarity threshold (Similarity Threshold) is set too high, filtering out slightly less relevant documents, or the Chunk size (Chunk Size) is too short, fragmenting key information and affecting recall.
Symptom: The model inaccurately references pharmacokinetic parameters or statistical conclusions. Reason: The knowledge base lacks semantic understanding optimization for professional terminology and units, or the Recall count (Recall Count) is insufficient to cover all relevant context.
Symptom: After a user query, the system frequently switches to other product knowledge bases, failing to consistently answer bioequivalence-related questions. Reason: The classification module or intent recognition configuration is overly sensitive, failing to correctly identify the domain consistency of the user's continuous questioning.

How to Confirm Proper Configuration

For typical bioequivalence queries, check if the sourceid referenced in the model's response precisely corresponds to the specific page number or section of the original report.
Randomly sample the cited content from the model's output and manually verify its complete consistency with the wording, data, and conclusions in the original document. Also, verify the numerical values and units of pharmacokinetic parameters.
Simulate queries of varying complexity, especially scenarios involving cross-referencing across multiple documents. Evaluate if the system consistently provides multi-source references and check if the Rerank result count (Rerank Return Count) effectively filters for the most critical evidence.

Note: The values provided are common starting points. Measure them against your own samples for optimal results.

Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.